Identification of a shared F8 mutation in the Korean patients with acquired hemophilia A by Hwang, Sung Ho et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0)
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
VOLUME 46ㆍ NUMBER 1ㆍ March 2011
THE KOREAN JOURNAL OF HEMATOLOGY CASE REPORT
Identification of a shared F8 mutation in the Korean patients with 
acquired hemophilia A
Sung Ho Hwang
1, Jeong A Lim
1, Hugh Chul Kim
2, Hyun Woo Lee
2, Hye Sun Kim
1
1Department of Biological Science, College of Natural Sciences, 
2Department of Hematology-Oncology, School of Medicine, Ajou 
University, Suwon, Korea
p-ISSN 1738-7949 / e-ISSN 2092-9129
DOI: 10.5045/kjh.2011.46.1.49
Korean J Hematol 2011;46:49-51.
Received on November 18, 2010
Revised on December 16, 2010
Accepted on January 26, 2011
Although uncommon, acquired hemophilia A (HA) is associated with a high rate of mortal-
ity due to severe bleeding. In spite of many hypotheses regarding the cause of acquired 
HA, there is as yet no established theory. In this study, we investigated the possibility that 
mutation(s) in the F8 gene may be correlated with the development of inhibitory 
autoantibodies. Direct sequencing analysis was performed on all 26 exons of the F8 gene 
of 2 patients exhibiting acquired HA. Both patients were found to share a common point 
mutation (c.8899G＞A) in the 3'-untranslated region (3'-UTR) of exon 26. This is the first 
report on the genotyping of F8 in the context of acquired HA.
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INTRODUCTION
  Although the incidence of acquired hemophilia A (HA) 
is low in the general population, i.e., approximately 1-4 
cases per million annually, it is a potentially life-threatening 
bleeding disorder. HA is characterized by the development 
of autoantibodies directed against plasma clotting factors, 
most frequently coagulation factor VIII (FVIII) [1, 2]. The 
development of autoantibodies leads to FVIII deficiency, 
which results in insufficient generation of thrombin [3]. 
Acquired HA is one of several autoimmune diseases, in which 
patients previously experienced normal hemostasis [4]. The 
age distribution of patients with acquired HA follows a bipha-
sic trend, with a minor peak in young postpartum women 
and a major peak at 60-80 years in patients with other auto-
immune disorders [2]. Although acquired HA is thought 
to be related to dysfunction of the immune system, the 
cause of this disorder remains unclear.
  The F8 genotype is important in the molecular diagnosis 
of HA as well as for the prediction of risk factors pertaining 
to the development of inhibitory autoantibody. Mutations 
associated with the absence of the gene product lead to 
a phenotype indicative of severe HA. Patients with this dis-
order are more prone to developing inhibitors. Oldenburg 
and Pavlova [5] have previously described the relationship 
between mutations and inhibitor development: multi-do-
main large deletions pose an extremely high risk (88%) for 
the development of inhibitors, and single-domain large dele-
tions, nonsense mutations, intron 22 inversions, and small 
deletions have risk probabilities of 25%, 31%, 21%, and 
16%, respectively. However, the F8 genotype in patients 
with acquired HA has not been studied in detail. In addition, 
the genotype database for acquired HA is not sufficient to Korean J Hematol 2011;46:49-51.
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Fig. 1. F8 mutation in acquired he-
mophilia A. Genomic DNA was pu-
rified from 2 patients and sequences
were analyzed by direct sequencing 
of all 26 exons using 35 synthesized 
primers. AMC-HA51 and AMC-HA52
indicate the patient ID. Mismatch 
site, c.8899G＞A, located in the 
3’-UTR region of exon 26, was iden-
tified using primer 33. F8-ref refers to
a wild-type F8 gene sequence (acce-
ssion no. NM_ 000132.3), which was
utilized as the reference gene.
understand the correlation between mutation type and auto-
antibody development. Therefore, profiling of mutation 
types by F8 genotyping is necessary.
CASE REPORT
  We examined the F8 genotype of 2 Korean patients with 
autoantibodies; one patient was a 71-year-old man (AMC- 
HA51), and the other was a 26-year-old woman (AMC-HA 
52). The 71-year-old man was transferred from Seoul St. 
Mary’s Hospital for the treatment of a bladder hematoma. 
He was treated with cryoprecipitate in Seoul St. Mary’s 
Hospital. Laboratory tests revealed that aPTT was 46 seconds, 
circulating FVIII level was 14.2%, and FVIII inhibitor was 
detected at 1.0 Bethesda units/mL. He was treated with ste-
roids and cyclophosphamide for 6 months. After ceasing 
all medications for acquired hemophilia, tests revealed that 
FVIII and inhibitor levels were normal. The 26-year-old 
woman presented with a 3-week history of right hip pain. 
Her laboratory data showed that aPTT was above 200 sec-
onds, and this was not corrected by normal FFP in a mixing 
test. Factor assay showed that circulating FVIII was 1.8% 
of the normal level and FVIII inhibitor was detected at 
110.2 Bethesda units/mL. In addition, FIX activity was 45.1% 
of the normal levels and FIX inhibitor was detected at 0.4 
Bethesda units/mL. Anti-nuclear antibody (ANA), hepatitis 
B-virus (HBV), hepatitis C-virus (HCV), and human im-
munodeficiency virus (HIV panels were negative and neither 
lupus anticoagulant nor anti-cardiolipin antibody was sig-
nificantly detected. To control acute bleeding, we started 
treatment with activated prothrombin complex concentrates 
(aPCC) (FEIBA) at 5,500 units, twice per day (100 IU/kg 
every 12 h). For inhibitor suppression, the immune sup-
pressants cyclophosphamide (50 mg/day) and prednisone (2 
mg/kg) were administered. The level of inhibitor decreased 
gradually and improvement in FVIII activity followed. After 
medication had been stopped, the inhibitor remained was 
undetectable.
  To profile the F8 genotype of these patients, we performed 
a direct sequencing analysis of all 26 exons, including the 
3'-untranslated region (UTR) and 5'-UTR, using 35 primers, 
which we have previously reported [6]. Genomic DNA was 
purified from the whole blood of 2 patients. Tests for in-
version mutations in intron 22 and intron 1, as well as gross 
exon deletion tests, were excluded because these mutations 
are known to cause congenital hemophilia or episodes of 
severe bleeding. A wild-type F8 gene sequence (accession 
no. NM_000132.3) served as the reference sequence. Finally, 
the mutation data were confirmed by using the CLC work-
bench program. Sequencing results revealed that the patients 
shared a common point mutation (c.8899G＞A; Fig. 1) in 
the 3'-UTR of exon 26.
DISCUSSION
  In this study, we found that 2 Korean acquired HA patients 
shared a common point mutation, c.8899G＞A, in the 3'-UTR 
of exon 26 of the F8 gene. This mutation is novel and has 
never been reported in the HAMSTeRS database. In a pre-
vious study, it was reported that some variants of the F8 
gene are related to non-congenital HA development [7]. 
The missense mutation, c.6238G＞A, caused a substitution 
in the A3 domain (E2004K). A second polymorphism, c.3951
C＞G, caused a further substitution in the B domain 
(D1241E). These 2 sequence variations are related to a human 
leukocyte antigen (HLA)-DRB1 genotype [7]. Thus, major 
histocompatibility complex (MHC) background could be a 
risk factor for inhibitor formation in non-congenital he-
mophilia. In addition, cytotoxic T lymphocyte antigen 4 
(CTLA4) has been reported to play an important role in 
the immune response [8]. Among the reported polymor-
phisms (−318C/T, 49A/G, and CT60 G/A), only the G allele 
of 49A/G has been detected at a significantly higher fre-
quency in acquired HA patients [8-11]. The above-mentioned 
high frequency of HLA class II alleles and SNPs in the CTLA4 
gene have been observed in acquired HA patients.
  In contrast to these mutations, which occurred in coding 
regions, the mutation found in this study is located in the 
3'-UTR region. Thus, we considered the possibility that this 
mutation is related to susceptibility to developing acquired Korean J Hematol 2011;46:49-51.
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HA. It has previously been reported that sequence variation 
in the 3'-UTR is associated with transcriptional mod-
ifications, splicing, or mRNA stability [12, 13]. In 5 families 
with hemophilia B (HB), a point mutation in the 3'-UTR 
of the F9 gene greatly reduced plasma FIX concentration 
to less than 3% of the normal level [14]. In addition, a 
653-bp deletion located in the 3'-UTR of the F9 gene was 
found to be responsible for mild HB [15]. Although these 
reports concern the F9 gene, we suggest that the novel muta-
tion in the 3'-UTR of the F8 gene discovered in cases of 
acquired HA may also be related to F8 mRNA stability or 
translational capacity. We surmise that an alteration in the 
stability of F8 mRNA and/or translational modifications leads 
to a synergetic triggering effect on antigen recognition be-
tween exogenous FVIII and endogenous FVIII. 
  Although the number of patients in this study is too few 
to make any important conclusions regarding the cause of 
acquired HA, we expect that the novel mutation discovered 
in this study may contribute to our understanding of the 
cause(s) of acquired HA. To the best of our knowledge, 
this is the first report on the genotyping of F8 in the Korean 
patients with acquired HA. Additional genotyping data from 
acquired HA patients will help us to determine more precise 
correlations between F8 genotype and the development of 
autoantibodies.
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